KRAS and non-small cell lung carcinoma: Based on our co-localization studies in Figure 5, using the PANC-1 pancreatic carcinoma cell line which expresses higher levels of K-RAS than the A549 NSCLC line, we determined whether our drug treatments altered the co-localization of K-RAS with ERBB1, and with the lysosomal associated proteins LAMP2 and cathepsin B. ERBB1 and K-RAS co-localized in PANC-1 cells, which was disrupted by exposure to neratinib, valproate and the drug combination (Figure 6A).